We have previously shown that increased IGF-1R signalling plays a key role in the development of acquired resistance to gefitinib in breast and prostate cancer cells (Jones et al, 2004) and we have postulated that such signalling, if present at high levels in cancer cells, may be responsible for de novo resistance to EGFR blockade. Here, EGFR is linked to cancer.